Characteristics | Values, n = 186 |
---|---|
PR3:MPO-ANCA+, n | 92:78 |
Diagnosis of GPA, MPA, EGPA, n | 92, 83, 11 |
Age at diagnosis, yrs, mean (SD) | 64.5 (15.8) |
Diagnosis delay, mos, median (IQR) | 2 (1–5) |
Laboratory results | |
CRP, mg/dl, median (IQR) | 8.7 (2.2–14.8) |
ESR, mm/h, mean (SD) | 67 (33) |
Hemoglobin, g/dl, mean (SD) | 11.0 (1.9) |
Thrombocyte count, × 109/l, mean (SD) | 381 (135) |
WBC count, × 109/l, median (IQR) | 11 (9–14) |
Creatinine, mg/dl, median (IQR) | 1.73 (0.84–3.47) |
Patients with ≥ 3 organ systems involved | 124 (67) |
Deaths during followup | 66 (36) |
Endstage renal disease* | 32 (17) |
Organ systems involved at diagnosis | |
General | 160 (86) |
Ear, nose, and throat | 79 (42) |
Chest | 88 (47) |
Nervous | 23 (12) |
Cutaneous | 15 (8) |
Mucocutaneous and eyes | 11 (6) |
Cardiovascular | 11 (6) |
Abdominal | 12 (6) |
Renal | 134 (72) |
↵* Information on endstage renal disease defined as either commencement of chronic dialysis or renal transplantation at any time during the followup from diagnosis to December 2011. ANCA: antineutrophil cytoplasmic antibody; AAV: ANCA-associated vasculitis; PR3: proteinase 3; MPO: myeloperoxidase; GPA: granulomatosis with polyangiitis; MPA: microscopic polyangiitis; EGPA: eosinophilic GPA; IQR: interquartile range; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; WBC: white blood cell.